Safety and Efficacy Study of BMS-908662 in Combination With Ipilimumab in Subjects With Advanced Melanoma



Status:Archived
Conditions:Skin Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:Any
Updated:7/1/2011
Start Date:January 2011
End Date:January 2013

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

A Phase 1 Study of a RAF Inhibitor (BMS-908662) Administered in Combination With Immunotherapy (Ipilimumab) in Subjects With Unresectable Stage III or Stage IV Melanoma


The purpose of the study is to identify a safe and tolerable dose of BMS-908662 in
combination with ipilimumab; and then to evaluate the anti-tumor response to BMS-908662 when
administered in combination with ipilimumab.



We found this trial at
2
sites
H. Lee Moffitt Cancer Center & Research Institute
12902 USF Magnolia Dr
Tampa, Florida 33612
(888) 663-3488
H. Lee Moffitt Cancer Center & Research Institute Moffitt Cancer Center in Tampa, Florida, has...
?
mi
from
Tampa, FL
Click here to add this to my saved trials
Jedd D. Wolchok, Md,Phd
New York, New York 10065
?
mi
from
New York, NY
Click here to add this to my saved trials